Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).
暂无分享,去创建一个
Y. Fujibayashi | P. Herrero | T. Sharp | J. Engelbach | Jason S. Lewis | R. Gropler | M. Welch | R. Laforest | A. Kovács | Jason S. Lewis
[1] Jason S. Lewis,et al. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships , 2002, JBIC Journal of Biological Inorganic Chemistry.
[2] C. Ling,et al. On measuring hypoxia in individual tumors with radiolabeled agents. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] Harumi Itoh,et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia , 2001, Annals of nuclear medicine.
[4] M. Welch,et al. A research resource in radionuclide research , 2001 .
[5] Y. Fujibayashi,et al. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] S Mutic,et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[7] J. Lacy,et al. Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] P. Cutler,et al. High purity production and potential applications of copper-60 and copper-61. , 1999, Nuclear medicine and biology.
[9] G. Johnson,et al. HL-91-Technetium-99m: A new marker of viability in ischemic myocardium , 1999, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[10] Zhonglin Liu,et al. 99mTc-HL91: "hot spot" detection of ischemic myocardium in vivo by gamma camera imaging. , 1998, Circulation.
[11] Y Yonekura,et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] C. Ng,et al. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. , 1995, Circulation.
[13] W. Rumsey,et al. Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] A. Nunn,et al. Nitroimidazoles and imaging hypoxia , 1995, European Journal of Nuclear Medicine.
[15] M. Parliament,et al. Imaging tumor hypoxia and tumor perfusion. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] M J Welch,et al. Quantification of Regional Myocardial Perfusion With Generator‐Produced 62Cu‐PTSM and Positron Emission Tomography , 1993, Circulation.
[17] M. Graham,et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] L. Golberg,et al. Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.
[19] M. Raichle,et al. Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] C. Dence,et al. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. , 1990, Journal of the American College of Cardiology.
[21] Y. Yonekura,et al. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] P. Herrero,et al. Quantitation of myocardial blood flow with H2 15O and positron emission tomography: assessment and error analysis of a mathematical approach. , 1989, Journal of computer assisted tomography.
[23] S. Cain,et al. Metabolic and circulatory responses of normoxic skeletal muscle to whole-body hypoxia. , 1989, Journal of applied physiology.
[24] C. Dence,et al. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] M. Cerqueira,et al. Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] B. Sobel,et al. Characterization of the functional significance of subcritical coronary stenoses with H(2)15O and positron-emission tomography. , 1985, Circulation.
[27] M. Ter-pogossian,et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. , 1982, The American journal of medicine.
[28] R. Kloner,et al. Early pathologic detection of acute myocardial infarction. , 1981, Archives of pathology & laboratory medicine.
[29] M. Fishbein,et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. , 1981, American heart journal.
[30] Ronald H. Huesman,et al. Imaging Properties of a Positron Tomograph with 280 Bgo Crystals , 1981, IEEE Transactions on Nuclear Science.
[31] G. Robinson,et al. THE ZINC‐62/COPPER‐62 GENERATOR: A CONVENIENT SOURCE OF COPPER‐62 FOR RADIOPHARMACEUTICALS , 1980, The International journal of applied radiation and isotopes.
[32] Y. Fujibayashi,et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] Y. Yonekura,et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. , 1999, Nuclear medicine and biology.
[34] S. Barrington,et al. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] M J Welch,et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.
[36] M. Green. A potential copper radiopharmaceutical for imaging the heart and brain: copper-labeled pyruvaldehyde bis(N4-methylthiosemicarbazone). , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.